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Available online 21 March 2011Abstract Cell based therapies for bone regeneration are an exciting emerging technology, but the availability of osteogenic cells
is limited and an ideal cell source has not been identified. Amniotic fluid-derived stem cells (AFS) and bone-marrow derived
mesenchymal stem cells (MSCs) were compared to determine their osteogenic differentiation capacity in both 2D and 3D
environments. In 2D culture, the AFS cells produced more mineralized matrix but delayed peaks in osteogenic markers. Cells were
also culturedon3D scaffolds constructed of poly-ε-caprolactone for 15 weeks.MSCsdifferentiatedmorequickly thanAFS cells on 3D
scaffolds, but mineralized matrix production slowed considerably after 5 weeks. In contrast, the rate of AFS cell mineralization
continued to increase out to 15 weeks, atwhich timeAFS constructs contained 5-foldmoremineralizedmatrix thanMSC constructs.
Therefore, cell source should be taken into consideration when used for cell therapy, as the MSCs would be a good choice for
immediate matrix production, but the AFS cells would continue robust mineralization for an extended period of time. This study
demonstrates that stem cell source can dramatically influence the magnitude and rate of osteogenic differentiation in vitro.
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doi:10.1016/j.scr.2011.03.001IntroductionLittle is known about the optimal cell source for tissue
engineering of cell-based therapies for musculoskeletal
tissues. Bone graft substitutes composed of a biodegradable
scaffold containing stem cells capable of osteogenic differen-
tiation have shown promise as an alternative to bone grafting.
18 A. Peister et al.or delivery of osteoinductive proteins. This cellular aug-
mentation is especially important in clinical cases where
endogenous cellular supply is diminished, such as in older
patients, smokers, or after chemotherapy or radiation
therapy.
Mesenchymal stem cells (MSCs) are believed to be the
source of osteoblastic cells during normal bone growth and
remodeling and may be isolated from the bone marrow,
among other tissues. Mesenchymal stem cells are a sub-
population of bone marrow-derived cells characterized by
their ability to differentiate to the mesenchymal lineage
tissues of bone, fat and cartilage, as well as muscle (Owen
and Friedenstein, 1988; Owen et al., 1987; Bruder et al.,
1998; Tsutsumi et al., 2001; Sekiya et al., 2002; Johnstone
et al., 1998; Wakitani et al., 1995). Additionally, MSCs can be
isolated from the intended recipient, thus reducing the
probability of rejection (Eliopoulos et al., 2005). Their
relative ease of isolation and differentiation capability
makes MSCs potentially useful for many applications,
including bone deficits (Caplan, 2005). Osteogenic differen-
tiation of MSCs has been well characterized. With the
addition of selected supplements to the basal growth
media, often referred to as osteoinductive factors including
dexamethasone, B-glycerophosphate and ascorbic acid,
MSCs will mineralize the surface of a two-dimensional
surface (Owen et al., 1987; Peister et al., 2004; Marie and
Fromigue, 2006). Furthermore, MSCs have been used in 3D
constructs to mineralize bone graft substitutes (Hutmacher
et al., 2001; Cartmell et al., 2004; Porter et al., 2007).
Human amniotic fluid-derived stem (AFS) cells are
isolated from amniotic fluid after routine amniocentesis
(Choi et al., 2011; De Coppi et al., 2007a; Delo et al., 2006;
Cananzi et al., 2009; In 't Anker et al., 2003; Prusa et al.,
2003; Tsai et al., 2004; Roubelakis et al., 2007). The AFS cells
express both embryonic and adult stem cell markers and are
broadly multipotent; they can be induced to differentiate
into cells representing all three embryonic lineages, such as
cells of the osteogenic, adipogenic, chondrogenic, myogen-
ic, endothelial, neuronal, and hepatic lineages (Delo et al.,
2006; De Coppi et al., 2007b; Kolambkar et al., 2007; Ditadi
et al., 2009; Zheng et al., 2009; Cipriani et al., 2007; Carraro
et al., 2008; Hauser et al., 2010). Unlike embryonic stem
cells, AFS cells are not tumorigenic and can expand
extensively without the use of feeder layers or expensive
defined media (De Coppi et al., 2007b). The AFS cell lines
have been shown to expand over 250 population doublings
and retain telomere length and have a normal chromosomal
karyotype (De Coppi et al., 2007b). Therefore, AFS cells have
great potential for cellular tissue engineering. Previously,
AFS cells have been shown to be capable of producing robust
mineralized matrix in two-dimensional culture and through-
out a three-dimensional medical grade poly-ε-caprolactone
(PCL) scaffold and nanofibrous scaffolds (Kolambkar et al.,
2007; Peister et al., 2009; Sun et al., 2010; Peister et al.,
2008). This study compares the ability of the adult and fetal
stem cell sources to produce mineralized matrix in 2D and 3D
culture.
Tissue engineering strategies using an extracellular
matrix combined with stem cells capable of osteogenic
differentiation may therefore be used to develop bone graft
substitutes. The aim of this study was to compare two cell
sources for potential application in the tissue engineering ofbone graft substitutes. Comparison of human fetal-derived
AFS cells and MSCs for the production of bone graft
substitutes will help elucidate the most appropriate cell
source for particular applications and may suggest appropri-
ate delivery strategies. By culturing cells on 3D scaffolds, it
was determined that the AFS cells had greater osteogenic
potential overall, but they were observed to take longer to
differentiate than the MSCs.Results
2D differentiation
The morphology of the AFS cells was heterogeneous, but
overall there appeared to be two general morphologies with
one very small and compact and the other more spindle
shaped (Supplemental Figs. 1A and B). The MSCs were also
heterogeneous, but to a lesser extent than the AFS cells. The
MSCs were spindle shaped and visibly larger than the AFS
cells (Supplemental Fig. 1C). The AFS cells and MSCs both
differentiated into mineral producing cells when grown on
tissue culture plastic. The mineralized matrix was visualized
by the alizarin red S staining of calcium that covers the cells
(Supplemental Figs. 1D–F).Biochemical assay of 2D mineralized matrix
Although the staining appeared to be qualitatively similar
between the cell types (Supplemental Figs. 1D–F), when the
alizarin red was extracted and quantified, the AFS cells
demonstrated significantly more mineral deposition/staining
at 2 and 4 weeks (Fig. 1A). The increased mineralized matrix
was confirmed by calcium extraction and quantification by
Arsenazo III reagent (Fig. 1B). The AFS cell mineralized
matrix contained significantly more Calcium than the matrix
produced by the MSCs.Gene expression
The expression levels of mRNA for Runx2, Alkaline Phospha-
tase and Osteocalcin were examined during osteogenic
differentiation of the AFS cells and MSCs. Runx2 is a
transcription factor involved in regulating osteogenic and
chondrogenic differentiation and maintenance. Alkaline
Phosphatase (ALP) is a phosphatase associated with miner-
alized matrix production. Osteocalcin is a vitamin D and K
dependent protein produced by osteoblasts and is a common
marker of bone formation.
In all three genes analyzed, the MSCs had a peak in gene
expression betweendays 3 and 5 of differentiation (Figs. 1C–E).
The AFS cells did not show this initial peak in gene expression
but rather gradually increased expression over the 14 day
culture. The ALP gene expression is consistent with previously
reported findings that the MSCs have a higher ALP level at
1 week, at 2 weeks the levels are similar, and at 3 weeks the
AFS cells have a higher ALP level (Kolambkar et al., 2010). The
temporal differences in the gene expression support the
hypothesis that the AFS cells are in a more primitive state
and require additional time to differentiate into osteoblasts.
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Figure 1 (A) To compare theamount of alizarin red staining of themineralizedmatrix producedby the cells, thedyewas extractedand the
absorbance determined spectrophotometrically to determine the temporal changes inmineralizedmatrix. At 2 and 4 weeks the AFS cells had
produced significantlymoremineralizedmatrix than theMSCs. (B) Calciumdeposition by theAFS cells andMSCswas confirmed andquantified
using the Arsenazo III reagent at 4 weeks. The AFS cells deposited significantlymore calcium than the MSCs (pb0.001). Both the AFS cells and
MSCs deposited significantlymore calcium than their control counterpart (n=6, pb0.01). Real-time PCR quantification of Runx2 (C), Alkaline
Phosphatase (D) and Osteocalcin (E) illustrate the temporal fluctuation of mRNA typical of osteoblasts. The MSCs had an early increase in
transcript levels,which thendecreased.TheAFS cells requireda longer induction timebefore themRNA levelswere increased (n=3, Pb0.05).
19Cell sourcing for bone tissue engineeringOsteogenic differentiation in 3D PCL scaffolds
The AFS cells and MSCs were seeded onto PCL scaffolds with
lyophilized collagen. The lyophilized collagen filled the
scaffold pores to enhance cell retention and the composite
scaffolds were placed in non-cell binding plates to encourage
cell attachment. The seeding efficiencies of the cell types
were not significantly different (Fig. 4C). Both the AFS cells
and MSCs had visually occluded the pores by 5 weeks.
The mineralized matrix production by the cells was
quantified by microCT analysis. The 3D renderings of the
mineralized matrix are shown in Fig. 2. The AFS cells had
sparse mineral deposition at 3 and 5 weeks. By 10 weeks the
AFS cells had produced substantial mineral throughout the
PCL scaffold. Conversely, the MSCs showed more mineral
production at the early time points, and the mineral content
was not enhanced by the additional culture time. Addition-
ally, the spatial distribution of the mineralized matrix
appeared to be cell-source specific. The AFS cells routinely
produced mineral throughout the entire scaffold, whereas
the MSCs only produced mineral in the center of the scaffold,
even though there were cells found throughout the scaffold
(Figs. 2 and 5E, I, and M).The mineralized matrix production
by the AFS cells on 3D constructs is highly reproducible, as is
illustrated by four representative microCT images of each
cell line at 15 weeks, see Supplementary Data Fig. 3.Quantification of 3D mineralized matrix
The quantity of mineralized matrix was determined by the
microCT scan, and the averages are shown in Fig. 3A. The
MSCs produced significantly more mineral at the 3 and
5 week time points, but their mineralization capacity was
limited to the first few weeks in culture. Alternatively, the
AFS cells did not produce substantial mineralized matrix until
5 weeks in culture, with mineralized matrix production
increasing throughout the 15 weeks in culture. At 3 and
5 weeks, the MSCs had produced significantly more mineral-
ized matrix than the AFS cells (pb0.001), but by 15 weeks
the AFS cells had produced 3 times more mineralized matrix
than the MSCs (pb0.001). At all time points, cells grown in
osteogenic media produced more mineralized matrix than
those grown in control media (pb0.001).
Two AFS cell lines were available at the time of this study
and their differentiation potential was compared. Little
variability was seen in the osteogenic differentiation of the
A1 and H1 AFS cell lines. The mineralized matrix volume did
not differ until 15 weeks in culture at which time the H1 AFS
cells had produced more mineralized matrix than the A1 AFS
cells. Both AFS cell lines produced approximately 5 times the
mineralized matrix than the MSCs at 15 weeks. The AFS cell
control media constructs also had more mineralized matrix
than the MSC control constructs at 15 weeks (pb0.05), which
Figure 2 MSCs and AFS cells induced to produce mineralized matrix within the PCL scaffold. The scaffolds were aseptically scanned
by microCT at weeks 3, 5, 10 and 15. The mineral volume of the same scaffold is shown for the A1 AFS cells, H1 AFS cells, and MSCs to
illustrate the change in mineralized matrix over time. The mineralization of the PCL scaffold by the AFS cells is much more extensive,
with the mineral distributed throughout the scaffold. The mineral produced by the MSCs is primarily found on the interior of the
scaffold. N=12.
20 A. Peister et al.may indicate greater spontaneous differentiation of the AFS
cells in the absence of osteogenic cues.
Rate of 3D mineralization
The scaffolds were scanned sterile and returned to culture.
Therefore, the rate of mineralized matrix production was
determined by quantifying the new mineral volume since the
previous scan and dividing by the number of weeks between
scans. The average rate of mineralized matrix production
(Fig. 3B) by the MSCs was greater at 3 weeks than the AFS
cells (pb0.001). By 5 weeks, the rate of mineralization of the
cell types was not significantly different. At 10 and 15 weeks,
the AFS cells were producing mineralized matrix at a greater
rate than the MSCs (pb0.001). Additionally, at 10 and
15 weeks the MSCs were producing mineralized matrix with a
rate that is indistinguishable from the control cells.
Calcium content and cell number
The AFS cells produced significantly more mineralized
matrix, as analyzed by calcium concentration, than the
MSCs (Fig. 4A). Additionally, both the MSCs and AFS cells
produced significantly more mineralized matrix when placed
in osteogenic media than in control media (n=6, pb0.001).
This increased mineralization was not due to an increased
cell number, but to an increased matrix deposition as the AFS
cells and MSCs attached to the scaffold in comparablenumbers (Fig. 4C). The seeding efficiency was comparable
for both cell types on the PCL scaffold. After 15 weeks in
culture, both the AFS cell and MSC seeded scaffolds had
similar cell number whether cultured in control or osteogenic
media, as determined by DNA content (Fig. 4D). Therefore,
human AFS cells demonstrated an increased long-term
osteogenic differentiation and mineralized matrix produc-
tion capacity compared to human MSCs.
Cell viability
After 15 weeks in culture, cell viability was determined by a
live–dead assay that relied on the intracellular esterase
activity and plasma membrane integrity, two measures of
cell viability, to discriminate between live and dead cells.
Photomicrographs of the exterior surfaces (top, bottom and
exterior circumference) are shown (Fig. 4B). Additionally,
the cells at the interior of the scaffolds were examined by
cutting the scaffold longitudinally. It can be observed that
even after 15 weeks in culture, the cell viability is very high
in all the scaffolds.
Histology
Histological examination of the scaffolds after 15 weeks,
using resin embedding and microtome sectioning to 5 μm
followed by von Kossa staining revealed no mineralisation
for the control (MSCs in CCM) PCL scaffolds (Figs. 5A–D).
Figure 3 (A) The volume of mineralized matrix produced by
the osteogenic and control cells within the PCL scaffold was
determined by microCT. At all time points there was signifi-
cantly more mineral in the osteogenic scaffolds than the control
scaffolds (pb0.001). At 3 and 5 weeks, significantly more
mineral was produced by the MSCs than the AFS cells
(pb0.001). At 10 and 15 weeks, both AFS cell lines produced
significantly more mineral than the MSCs (pb0.001). At
15 weeks, the H1 AFS line also produced significantly more
mineral than the A1 cell line. N=6 for controls, n=12 for
osteogenic. (B) The rate of mineral deposition was calculated for
each scaffold and then compiled with its cohort. The rate of
mineral deposition was significantly higher in the osteogenic
MSCs at 3 weeks (pb0.001) when compared to osteogenic AFS
cells, but at 5 weeks the rate of mineralization between the
three osteogenic groups was not significantly different. At 10
and 15 weeks, the rate of mineralization of the osteogenic AFS
cell groups was significantly greater than the osteogenic MSCs.
At 15 weeks, the H1 mineralization rate was greater than the A1
AFS cell mineralization. At 10 and 15 weeks, the rate of
mineralization of the MSCs was not significantly different from
the control groups. N=6 for controls, n=12 for osteogenic.
(pb0.001). N=6 for controls, n=12 for osteogenic.
21Cell sourcing for bone tissue engineeringOnly pink stained fibrous tissue can be observed. Whereas
the onset of bone formation was observed for osteoinduced
MSC and AFS cells which were seeded into 3D PCL scaffolds.
Mineral nodules containing calcium, stain black with the von
Kossa staining by virtue of silver ions (positive charge)
binding with the mineralised tissue (negative portion of the
calcium salt) forming a silver salt which is black in color.
Clear black mineral deposition can be observed for
osteinduced MSCs (Figs. 5E–H) and AFS cells (I–P), within
a fibrous network penetrating the scaffold pores. ResidualPCL scaffold was evident within all transplants as evidenced
by voids in the tissue from longitudinal and transverse
sectioning of the scaffold struts. It can be noted that the
pattern of mineral deposition was different between each
cell type and seems to favor a more central scaffold locality
for MSC cells whereas the AFS cells seem to deposit
throughout the entire scaffold both centrally and at the
periphery.Discussion
This study demonstrates the mineralization potential of a
fetal and adult stem cell population. The fetal AFS cells
demonstrated an increased duration of mineralized matrix
production, but the MSCs were capable of robust differen-
tiation at the earlier time points. After 15 weeks in 3D
culture, the AFS cells had produced approximately 20 mm3 of
mineralized matrix, whereas the MSCs had produced
approximately 4 mm3 by 5 weeks, which did not increase
thereafter. MicroCT analysis showed that the mineralization
for MSC scaffold constructs was located mainly within the
central core of the scaffold as opposed to the AFS cells which
mineralized the entire scaffold including the outer edges.
In 2D culture, the AFS cells differentiate readily and using
a standard time course it is not evident that there is a lag in
differentiation by these cells. Quantitative PCR comparing
osteogenic gene expression between the two cell sources in
2D revealed a lag in the AFS cells when compared to the
MSCs. This supports the longer induction time necessary for
the AFS cells to differentiate to osteoblasts. The sensitivity
of the staining of the extracellular matrix in 2D culture was
not capable of determining these early differences in the cell
differentiation because by 14 days the gene expression by
the AFS cells matched or exceeded the expression in the
MSCs.
The 15 week in vitro culture protocol used in this study
provided a very challenging culture system to examine long
term potential of the cell sources. When grown in a large
6 mm×9 mm PCL scaffold, the AFS cells had great potential
but the cells required an extensive induction time prior to
their osteogenic differentiation. Current studies often
culture cells within 3D scaffolds for less than 6 weeks but
this time period would not have shown the potential of the
AFS cells. Early time points suggest that the MSCs have a
greater potential, but the AFS cells have a greater overall
mineralized matrix production capacity when examined
after an extensive culture period. This supports the
hypothesis that the AFS cells have a longer induction period
than the MSCs, which may be due to their fetal origins.
The mineral deposition distribution found by microCT was
supported by histological examination which demonstrated
that the pattern of black stained mineral deposition was
different between each cell type and seems to favor a more
central scaffold locality for MSC cells whereas the AFS cells
seem to deposit throughout the entire scaffold both centrally
and at the periphery. This could be due to the MSCs requiring
local mineral presence in order to nucleate more mineral
production which leads to a tendency to concentrate their
cells actively capable of mineralisation within the same area
(in the scaffold core in this case) whereas AFS cells might be
more capable of spontaneous mineralisation without requiring
Figure 4 (A) The calcium produced by the cells during the 15 weeks in culture was compared and quantified using the Arsenazo III
reagent. 25% of the scaffold was used for this comparison. The AFS cells produced significantly more mineralized matrix than the MSCs
when cultured in osteogenic media (pb0.001). Both cells produced significantly more mineralized matrix in osteogenic media than when
cultured in control media (pb0.001 for AFS cells, pb0.01 for MSCs). (B) Cell viability of the cells at 15 weeks in culture was determined by
Calcien AM staining for live cells and ethidium homodimer-1 staining of the nuclei of dead cells. The exterior surfaces (top, bottom and
outer surface) along with the middle of the scaffold (produced by cutting the scaffolds longitudinally) were visualized by confocal
microscopy. Few dead cells were seen in the scaffolds and cells can be seen throughout the scaffolds, including spanning the pore space
between the PCL struts. (C) The cell attachment of the AFS cells andMSCs to the PCL scaffolds was determined by cell count after 3 days in
culture.Nodifferenceswere seenbetween the twogroups. N=6. (D) The cell proliferation and survivalwas similar after the 15 weeks in 3D
culture, whether the scaffolds were seeded with MSCs or AFS cells and cultured in osteogenic or control media. N=6.
22 A. Peister et al.any prerequisite mineral existing in close proximity. Alterna-
tively the mineral nucleation sites (such as those present on
collagen or denatured collagen) (Taubenberger et al., 2010)
might have been distributed more centrally in the case of the
MSC scaffold constructs compared to the AFS scaffold
constructs. It certainly highlights the differences in miner-
alisation capacities of these different cells from a temporal,
spatial and rate perspective.
Serial microCT scans of scaffolds were performed which
allowed the determination of the change in matrix within
each scaffold over the 15 weeks in culture. The rate of
mineralized matrix production was higher for the MSCs at the
beginning of the culture but the cells did not produce
detectible mineralized matrix after the 5 week scan. The AFS
cells had a low rate of mineralization for the first 3 weeks,
but the rate increased thereafter and continued to increase
over the 15 weeks of culture. This may be due to the more
primitive state of the fetal AFS cells needing additional time
or cell density before they will differentiate to osteoblasts.
Although the rate of MSC mineralized matrix production
decreased after 5 weeks, the cells maintained high viability
throughout the culture. At 15 weeks, the cells were foundthroughout the scaffolds and there was minimal cell death in
scaffolds seeded with either cell type without bias for the
spatial localization within the scaffold. Additionally, the AFS
cells and MSCs had similar cell numbers attach to the scaffold
after 15 weeks in culture so the difference inmatrix production
was not due to cell proliferation or apoptosis. Maintaining the
high viability achieved in vitro will be imperative to have
similar results in vivo. The long induction time for the AFS cells
may make this even more challenging. Co-implantation of both
MSCs and AFS cells may prove beneficial as the MSCs could
provide immediate mineralized matrix production and the AFS
cells will provide long-term support.
Cell-based tissue engineering strategies represent a
clinical alternative to bone grafting and the delivery of
osteoinductive proteins (Kimelman et al., 2007). However,
cell sourcing is a critical issue for cell-based therapies which
aim to regenerate musculoskeletal tissues, and this issue
needs to be addressed (Caplan, 2005; Barrilleaux et al.,
2006). Tissue engineering approaches that combine biode-
gradable scaffolds with stem cells capable of osteogenesis
have shown promise as an effective bone graft substitute
(Meinel et al., 2004). Cell-based engineered bone grafts are
Figure 5 Histology revealed the onset of ectopic bone formation for osteoinduced MSC and AFS cells when seeded into 3D PCL
scaffolds and cultured for 15 weeks. MSC control cell scaffold show nomineralisation, only fibrous tissue formation, which stained pink
(A–D). Clear black mineral deposition can be observed for osteinduced MSCs (E–H) and AFS cells (I–P), within a fibrous network
penetrating the scaffold pores.
23Cell sourcing for bone tissue engineeringan attractive alternative to allografts or autografts, partic-
ularly when the endogenous supply of stem cells is depleted
through advanced age or concurrent therapy (Hutmacher
et al., 2001; Bruder and Fox, 1999; Salgado et al., 2004).
Several factors are critical for the choice of transplanted
cells, such as: a) availability in sufficient numbers for
therapeutic use, b) immune-tolerance, and c) the ability to
promote bone formation on a therapeutic timescale.
Despite well known developmental differences in tissue
regeneration and scar formation, very little is known about
the differences in phenotype and regenerative capacity of
stem cells isolated from different human developmental
stages. Although there is evidence that allogeneic stem cells
promote bone repair, many tissue-engineering studies have
been limited by a lack of quantitative outcome measures
to allow direct comparisons between different stem cell
sources. Purified mesenchymal stem cells (MSCs) derived
from bone marrow have been shown to enhance repair of
critically sized defects in preclinical animal studies (Bruder
and Fox, 1999; Sanchez-Guijo et al., 2009).
Many questions still remain pertaining to the use of stem
cells for regenerative medicine. Although we have shown
that the AFS cells have an increased osteogenic capacity than
the MSCs in vitro, the comparison of this capacity in vivo is of
greater clinical significance. Critical factors are still un-
known for the optimal delivery strategy, such as: a) should
the cells be undifferentiated or pre-differentiated in culture
prior to implantation, b) are exogenous factors such as pro-angiogenic growth factors important for revascularization, c)
what is the optimal time point for implantation post-trauma,
and d) howmany cells should be delivered and should they be
implanted in one site as a bolus or at multiple implantation
sites or specific designated times? There is vast potential for
stem cells in regenerative medicine, and determining the
optimal cell source will certainly improve patient outcome.Methods
Amniotic fluid stem cell culture
Human AFS cells were kindly provided by the Institute for
Regenerative Medicine at Wake Forest University (De Coppi et
al., 2007b). In this study, two cell lineswere available and both
were analyzed, A1 and H1 human AFS cells. The AFS cells
were received at passage 14, and further expanded 2–3 times
in α-MEM medium containing 15% FBS, 2 mM L-glutamine, 100
units penicillin, 100 μg streptomycin (all Invitrogen, Carlsbad,
Ca), supplemented with 18% Chang B and 2% Chang C (Irvine
Scientific, Santa Ana, CA) at 37 °C with 5% CO2 atmosphere.
This media is referred to in this paper as modified Chang
media. AFS cellswere sub-cultured at a dilution of 1:10 andnot
permitted to expand beyond 70% confluence in the modified
Changmedia on Integrid plates (BD Falcon, San Jose, CA). Cells
were frozen in the modified Chang media supplemented with
5% DMSO. For experimental use, 1×106 AFS cells were quickly
24 A. Peister et al.thawed to 37 °C and placed in 10, 150-mm Integrid culture
plates withmodified Changmedia. After 5 days, the cells were
harvested with 0.25% trypsin–EDTA (Invitrogen), counted and
used experimentally.
Mesenchymal stem cell culture
Human MSCs were generously provided by the Texas A%M
University Health Science Center through the NIH-funded
center for preparation and distribution of adult stem cells
(5P40RR017447-08). MSCs from four adult donors were
expanded by plating the cells at an initial density of 50 cells/
cm2 and cultured in complete culture media (CCM) or also
referred to as Control Media. CCM consists of alpha-modified
minimal essential media (αMEM, Invitrogen) supplemented
with 17% FBS (Atlanta Biologicals), 2 mM L-glutamine, 100 units
penicillin, 100 μg streptomycin (all Invitrogen). Cells were
cultured on tissue culture dishes (Nuncleon Δ surface, Thermo
Fisher, Rochester, NY). After 7–9 days, the cells were
harvested with 0.25% trypsin–EDTA (Invitrogen), counted and
used experimentally. Cells were not permitted to expand
beyond 70% confluence and were frozen in αMEM supplemen-
ted with 30% serum and 5% DMSO. For experimental use, all
four MSC donor cells were quickly thawed to 37 °C and placed
in four 10-mm Nuncleon culture plates with CCM to recover
from freezing. The next day the cells were removed from the
plates with trypsin–EDTA and counted. Equal quantities of
each donor MSCs were combined and placed in Nuncleon
culture plates at 50 cells/cm2. After 7 days, the cells were
harvested with 0.25% trypsin–EDTA, counted and used
experimentally.
Osteogenic differentiation
AFS cells or MSCs were cultured at 20,000 cells/cm2 in 6 well
plates (Nunc, Rochester, NY) in either modified Chang media
(AFS cells) or CCM (MSCs), N=6 for all conditions. After
allowing the cells to attach to the culture dish for 24 h, the
media was changed to the osteogenic induction conditions,
which comprised CCM media supplemented with 1 μM
Dexamethasone, 6 mM β-glycerol phosphate, 50 μg/ml
Ascorbic acid 2-Phosphate, and 50 ng/ml Thyroxine (all
Sigma, St. Louis, MO) (Peister et al., 2004, 2008). Control
samples of both MSCs and AFS cells were grown in CCM to
exclude spontaneous differentiation. The media was chan-
ged 2 times per week. Cells were analyzed 2 and 4 weeks
after the start of differentiation.
Alizarin red S staining for calcium
The cells were washed with excess PBS (Mg2+ and Ca2+ free,
Invitrogen) and fixed in 10% neutral buffered formalin
(Sigma) for 15 min. The cells were washed 3× with water,
then stained with 2 ml 0.4 mM Alizarin red S (pH 4.2, Sigma)
for 20 min with rocking. Calcium forms an alizarin red S-
calcium complex in a chelation process, producing a dark red
stain. The excess Alizarin red S stain was removed and using
vigorous washing with excess water (4 times for 5 min each,
with rocking). Stained monolayers were visualized by phase
microscopy using an inverted microscope (Nikon, Melville,
NY).Gene expression by real-time RT-PCR
For each cell type, 50,000 cells/cm2 were placed into 6 well
dishes and cultured overnight in CCM. After allowing the cells
to attach to the culture dish for 24 h, the media was changed
to osteogenic media and the media was changed every 3 days
throughout the culture. Cells were harvested at days 0, 1, 2,
3, 5, 7, 10 and 14 using a cell scraper (Nunc) and the RNA was
isolated using Qiagen RNEasy Plus kit according to the
manufacturer's instructions. cDNA was produced from 1 μg
total RNA using Superscript III First-strand Synthesis SuperMix
according to manufacturer's instructions (Invitrogen). Real-
time PCR was performed on a StepOnePlus Real-Time PCR
System (Applied Biosystems) with Power Sybr Green PCR
Master Mix (Applied Biosystems). The cycle threshold was
normalized to GapDH and compared to a relative standard
curve for each primer set. Primer sequences and concentra-
tions are given in Supplimentary Table S1.Scaffold preparation
3-dimensional sheets of PCL lattice comprised of 300 μm
struts spaced 500 μm apart in a 0, 60, 120 degree repeating
pattern with 85% porosity and a height of 9 mm were
produced through fused deposition modeling as previously
described (Porter et al., 2007; Peister et al., 2009) with a
height of 9 mm. Cylinders of a 6 mm diameter were cut from
the sheet with a dermal biopsy punch (Miltex, York, PA). The
cylinders were incubated in 5 M NaOH for 2 h at 37 °C to
clean and partially degrade the scaffold surface, thereby
increasing surface roughness. The scaffolds were then
washed 3× in excess sterile water and sterilized through
70% ethanol evaporation.
To produce a collagen network throughout the pores of the
PCL lattice, a collagen gel was produced with type 1 rat tail
collagen (Vitrogen, Fremont, CA). Briefly, 100 parts collagen
(1.4 mg/ml in 0.05% acetic acid) was combined with 9 parts
sodium bicarbonate, and 250 μl was placed in a custom mold.
The PCL cylinderwas then placed in themold/collagen and the
collagen allowed to gel for 30 min at room temperature, and
then cooled to −80 °C for 2 h. The PCL/collagen was then
placed in a lyophilizer overnight (Labconco, Kansas City, MO).
After lyophilization, the scaffolds were removed from the
mold and placed in a 12 well tissue culture dish (Nunc, low cell
binding). To maintain scaffold orientation during culture, the
cylinders were placed in a holder consisting of a sterile 3/4"
Teflon disk with 4 stainless steel pins surrounding the cylinder.Cell seeding onto PCL/collagen scaffolds
AFS cells and MSCs were expanded as described above. Six
million cells were resuspended in 150 μl of modified Chang
media or CCM and slowly placed drop-wise on the top of the
scaffold. The media were readily absorbed by the collagen
mesh, with minimal pooling at the bottom. The cell/scaffold
was placed in the 37 °C incubator for 1 h to promote cell
attachment, after which time 4 ml of modified Chang media
or CCM was carefully added to each well. The scaffolds were
cultured under static conditions for 3 days to allow the cells
to attach to the scaffold.
25Cell sourcing for bone tissue engineeringAfter 3 days, the media was carefully aspirated and
osteogenic media was added to each osteogenic sample and
control samples were cultured in CCM. At this time, the
scaffolds were placed on a rocker plate to increase media
perfusion through the scaffold (Belly Button® orbital shaker,
7.5 rpm, minimal pitch, Stovall, Greensboro, NC). The media
was changedevery 2–3 days for 15 weeks (Peister et al., 2008).
The seeding efficiency was determined at day 3, prior to the
placement in osteogenic media. The scaffolds were washed 2×
with PBS to remove unattached cells. The scaffolds were then
immersed in 1 ml of trypsin–EDTA for 5 min at 37 °C. The trypsin
was inactivated with 5 ml complete culture media and the cells
pelleted by centrifugation at 450×g for 10 min. The cell pellets
were resuspended in 3 ml CCM, stained with trypan blue and
counted in duplicate on a hemocytometer. N=4.Microcomputed tomography scanning
At 3, 5, 10, and 15 weeks, the scaffoldswere removed from the
Teflon holders and placed in a sterile polysulfone sample
holder.Mineralization of the scaffoldswas quantified using the
VivaCT (Scanco Medical, Switzerland) at a 21.5 voxel
resolution. Samples were evaluated at a threshold of 80, a
filter width of 1.2, and filter support of 1. For each scaffold, a
measurement of the volume filled with hydroxyapatite was
determined. The samples were then removed aseptically from
the sampleholder and returned to theTeflonholder for further
culture. N=12.Calcium assay
At 15 weeks in either osteogenic or control media, the
scaffold was dissected into 4 sections by slicing in a custom
matrix so that each scaffold was cut vertically across the
diameter of the cylinder and horizontally to produce 4
sections of equal size. ¼ of the scaffold, ½ of the top half of
each scaffold, was used to determine the calcium within the
matrix. Each scaffold was placed in 500 μl of 1 M acetic acid
and placed on a vortex overnight at 4 °C to extract the
calcium from the mineralized matrix.
In a 96 well clear polycarbonate plate, 25 μl of cell
extract were mixed with 300 μl of calcium reagent (Arsenazo
III, Diagnostic Chemicals Limited) and the absorbance
determined at 615-nm with a spectrophotometer. N=6.DNA assay
The PicoGreen DNA quantification kit (Invitrogen) was used
to following the protocol recommended by the manufacturer
to determine at 15 weeks the relative amount of DNA within
scaffolds from the different experimental groups. Lambda
DNA standards were produced from 1 μg to 1 ng. The cell
lysates were diluted 1:10 in Tris–EDTA buffer. 100 μl of the
PicoGreen working solution and 100 μl of each sample were
placed in triplicate, in black 96-well plates. After a 5-minute
incubation, the fluorescence was determined at an excita-
tion of 485-nm and an emission of 535-nm (Perkin-Elmer HTX
7000 fluorescent plate reader, Waltham, MA). N=6.Cell viability staining
Cell viability at 15 weeks was determined using the LIVE/
DEAD Viability/Cytotoxicity Kit for mammalian cells accord-
ing to manufacturer's instructions (Molecular Probes, Invitro-
gen). Briefly, scaffolds were cut longitudinally and washed 3
times in excess PBS and then incubated for 45 min in 4 μM
Calcein AM and 4 μM Ethidium homodimer-1 with gentle
shaking. The scaffolds were then washed 3 times with PBS
and analyzed using a confocal microscope (LSM 510 UV, Carl
Zeiss, Thornwood, NY). Micrographs were taken on the
exterior surfaces: top, bottom, and outside surfaces as well
as the cut surface to check the viability at the core of the
scaffold.
Histology
For histological examination, scaffolds were removed from
culture at 15 weeks and fixed in 4% paraformaldehyde. An
ethanol gradient (30 min in 70%, 1 h in 90%, 95% and 100%
ethanol) was used to dehydrate the samples. They were next
processed three times through xylenes for 40 min each,
infiltrated with methylmathacrylate (MMA) for 3 h and
embedded in MMA containing 3% PEG softener. Five
micrometer sections were cut with an osteomicrotome
(SM2500; Leica Microsystems, Wetzlar, Germany), stretched
flat with 70% ethanol onto a polylysine coated microscope
slide (Lomb Scientific), overlayed with a plastic film and
slides were clamped together before being dried overnight at
50 °C. Sections were then stained using combined von Kossa
and van Giesen stains to visualize the mineralised bone and
connective tissue respectively (Reichert et al., 2010).
Data analysis
Data are reported as mean±SE and statistical analyses was
performed using Graphpad Prism 5 software using a general
linear model (ANOVA) and Tukey's post-hoc analysis with
Bonferroni adjustment or pair wise comparisons; with
pb0.05 considered significant.
Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2011.03.001.Acknowledgments
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